Vol. 20.C January - February 2021 | Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access

Indexed in:

Scopus, Web of Science, Medline/PubMed, DOAJ and Conacyt

Mario Peribañez-Gonzalez, Hugo Cheinquer, Lino Rodrigues, Maria Patelli Lima, Mário Reis Álvares-da-Silva, José Madruga, Edison Roberto Parise, Mário Guimarães Pessoa, Juvencio Furtado, Marcia Villanova, Adalgisa Ferreira, Felipe Mazzoleni, Ecio Nascimento, Giovanni Faria Silva, Linda Fredrick, Preethi Krishnan, Margaret Burroughs, Tania Reuter

Ann Hepatol. 2021;20C:257

Open access

Cost of illness of liver diseases in Japan

Kunichika Matsumoto, Yinghui Wu, Shigeru Fujita, Kanako Seto, Yosuke Hatakeyama, Ryo Onishi, Tomonori Hasegawa

Ann Hepatol. 2021;20C:256

Highlights

•
The COI of liver diseases in Japan has been decreasing for the past 15 years.
•
The COI of hepatitis C continued to decline despite the advent of expensive drugs.
•
The emergence of effective DAAs is expected to reduce the COI of all liver diseases.

Open access

The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies

Umar Hayat, Ali A. Siddiqui, Hayrettin Okut, Saba Afroz, Syed Tasleem, Ahmed Haris

Ann Hepatol. 2021;20C:254

Open access

Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease

José Tadeu Stefano, Laura Vilar Guedes, Arthur Alencar Arrais de Souza, Denise Siqueira Vanni, Venâncio Avancini Ferreira Alves, Flair José Carrilho, Alvaro Largura, Marco Arrese, Claudia P. Oliveira

Ann Hepatol. 2021;20C:253

Open access

Clinical evaluation of modified ALPPS procedures based on risk-reduced strategy for staged hepatectomy

Jie Li, Guang-Sheng Yang, Ke-Jian Sun, Yan Ma, Xiao-Wang Bi, Xu Han

Ann Hepatol. 2021;20C:245

Open access

PNPLA3 rs738409 associates with alcoholic liver cirrhosis but not with serum levels of IL6, IL10, IL8 or CCL2 in the Russian population

Danil I. Peregud, Valeria Yu. Baronets, Anna S. Lobacheva, Alexandr S. Ivanov, Olga S. Arisheva, Irina V. Garmash, Zhanna D. Kobalava, Sergey V. Pirozhkov, Natalia N. Terebilina

Ann Hepatol. 2021;20C:247

Open access